MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

118.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
29 30 Next >
News headline image
INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Attractive Valuation ↗
INCYTE CORP (NASDAQ:INCY) presents a value opportunity with strong profitability, financial health, and an undervalued forward P/E. Analysts expect earnings growth despite a slight revenue decline. 
Via Chartmill
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
3 Cash-Producing Stocks with Questionable Fundamentals
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
3 S&P 500 Stocks Skating on Thin Ice
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
A Look at Incyte's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Incyte (INCY) Q2 Earnings: What To Expect
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday morning. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
From Incyte
Via Business Wire
News headline image
1 Value Stock Worth Your Attention and 2 Facing Headwinds
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Topics Supply Chain
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Top S&P500 movers in Friday's session ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis. 
Via Stocktwits
Topics Intellectual Property
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Thursday's session: top gainers and losers in the S&P500 index ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
News headline image
Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
News headline image
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
From Incyte
Via Business Wire
News headline image
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Undervalued Potential ↗
INCYTE CORP (NASDAQ:INCY) shows strong valuation, profitability, and financial health, making it an interesting pick for value investors. The stock trades at a discount to peers with solid growth... 
Via Chartmill
News headline image
3 Low-Volatility Stocks with Questionable Fundamentals
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
3 Unpopular Stocks in Hot Water
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Monday? 
Via Chartmill
News headline image
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses ↗
Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development. 
Via Benzinga
News headline image
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
News headline image
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
News headline image
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
From Incyte
Via Business Wire
News headline image
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story